Antiviral antibiotic BU-3889V
    1.
    发明授权
    Antiviral antibiotic BU-3889V 失效
    抗病毒抗生素BU-3889V

    公开(公告)号:US5098708A

    公开(公告)日:1992-03-24

    申请号:US546463

    申请日:1990-07-06

    IPC分类号: C12P1/06

    摘要: Production of an antiviral antibiotic complex, BU-3889V and its bioactive components A.sub.1, A.sub.2, A.sub.3, D.sub.1, D.sub.2 and D.sub.3, by fermentation of a BU-3889V producing strain of the new microorganism Amycolatopsis orientalis ATCC-53884 is disclosed. Complex BU-3889V is recovered and the components separated by the use of ion exchange chromatography techniques. The bioactive components are characterized by their physico-chemical characterizing properties. The products have been found to be effective to inhibit viruses including herpes simplex virus, human immunodeficiency virus (HIV) and influenza virus.

    摘要翻译: 公开了通过新型微生物Amycolatopsis orientalis ATCC-53884的BU-3889V生产菌株的发酵生产抗病毒抗生素复合物BU-3889V及其生物活性成分A1,A2,A3,D1,D2和D3。 通过使用离子交换色谱技术分离复合物BU-3889V并将组分分离。 生物活性成分的特征在于其物理化学性质。 已经发现这些产品有效地抑制包括单纯疱疹病毒,人类免疫缺陷病毒(HIV)和流感病毒在内的病毒。

    Process for preparing antiviral antibiotic BU-3889V
    2.
    发明授权
    Process for preparing antiviral antibiotic BU-3889V 失效
    制备抗病毒抗生素BU-3889V的方法

    公开(公告)号:US5124150A

    公开(公告)日:1992-06-23

    申请号:US624029

    申请日:1991-03-11

    IPC分类号: C12P1/06

    CPC分类号: C12P1/06 Y10S435/822

    摘要: Production of an antiviral antibiotic complex, BU-3889V and its bioactive components A.sub.1, A.sub.2, A.sub.3, D.sub.1, D.sub.2 and D.sub.3, by fermentation of a BU-3889V producing strain of the new microorganism Amycolatopsis orientalis ATCC-53884 is disclosed. Complex BU-3889V is recovered and the components separated by the use of ion exchange chromatography techniques. The bioactive components are characterized by their physico-chemical characterizing properties. The products have been found to be effective to inhibit viruses including herpes simplex virus, human immunodeficiency virus (HIV) and influenza virus.

    摘要翻译: 公开了通过新型微生物Amycolatopsis orientalis ATCC-53884的BU-3889V生产菌株的发酵生产抗病毒抗生素复合物BU-3889V及其生物活性成分A1,A2,A3,D1,D2和D3。 通过使用离子交换色谱技术分离复合物BU-3889V并将组分分离。 生物活性成分的特征在于其物理化学性质。 已经发现这些产品有效地抑制包括单纯疱疹病毒,人类免疫缺陷病毒(HIV)和流感病毒在内的病毒。

    Boholmycin antibiotic
    6.
    发明授权
    Boholmycin antibiotic 失效
    博尔霉素抗生素

    公开(公告)号:US4792545A

    公开(公告)日:1988-12-20

    申请号:US817212

    申请日:1986-01-08

    CPC分类号: C07H15/234 C12P19/46

    摘要: Boholmycin antibiotic is prepared by fermentation of Streptomyces hygroscopicus H617-25 (ATCC No. 53240) in a nutrient medium preferably comprising glycerol, bacto-liver, cornsteep liquor, ammonium sulfate, sodium chloride and calcium carbonate. The antibiotic and pharmaceutically acceptable salts and hydrates thereof and compositions containing these are effective against Gram-positive, Gram-negative and acid-fast bacteria and against bacterial strains which are resistant to previously known aminoglycoside antibiotics and are useful to treat bacterial infections in mammals.

    摘要翻译: 通过在优选包含甘油,细菌肝,玉米浸液,硫酸铵,氯化钠和碳酸钙的营养培养基中发酵吸水链霉菌H617-25(ATCC No.53240)来制备博尔霉素抗生素。 抗生素及其药学上可接受的盐和水合物以及含有它们的组合物对革兰氏阳性,革兰氏阴性和酸性抗菌细菌和对先前已知的氨基糖苷类抗生素具有抗性的细菌菌株是有效的,并且可用于治疗哺乳动物的细菌感染。

    Antiviral antibiotic BU-3889V
    7.
    发明授权
    Antiviral antibiotic BU-3889V 失效
    抗病毒抗生素BU-3889V

    公开(公告)号:US5286649A

    公开(公告)日:1994-02-15

    申请号:US819543

    申请日:1992-01-10

    CPC分类号: C12P1/06 Y10S435/822

    摘要: Production of an antiviral antibiotic complex, BU-3889V and its bioactive components A.sub.1, A.sub.2, A.sub.3, D.sub.1, D.sub.2 and D.sub.3, by fermentation of a BU-3889V producing strain of the new microorganism Amycolatopsis orientalis ATCC-53884 is disclosed. Complex BU-3889V is recovered and the components separated by the use of ion exchange chromatography techniques. The bioactive components are characterized by their physico-chemical characterizing properties. The products have been found to be effective to inhibit viruses including herpes simplex virus, human immunodeficiency virus (HIV) and influenza virus.

    摘要翻译: 公开了通过新型微生物Amycolatopsis orientalis ATCC-53884的BU-3889V生产菌株的发酵生产抗病毒抗生素复合物BU-3889V及其生物活性成分A1,A2,A3,D1,D2和D3。 通过使用离子交换色谱技术分离复合物BU-3889V并将组分分离。 生物活性成分的特征在于其物理化学性质。 已经发现这些产品有效地抑制包括单纯疱疹病毒,人类免疫缺陷病毒(HIV)和流感病毒在内的病毒。

    BMY-28121, a new antitumor antibiotic
    8.
    发明授权
    BMY-28121, a new antitumor antibiotic 失效
    BMY-28121,一种新的抗肿瘤抗生素

    公开(公告)号:US4935362A

    公开(公告)日:1990-06-19

    申请号:US31955

    申请日:1987-03-30

    IPC分类号: C07D487/04 C12P17/18

    摘要: A new antitumor antibiotic designated herein as BMY-28121 is produced by fermentation of Streptomyces albus strain K7331-113 (ATCC 39897). BMY-28121, which may be recovered from the fermentation broth in either its natural free hydroxy form (BMY-28121A) or methyl ether form (BMY-28121B), inhibits gram-positive bacteria and anaerobes and inhibits the growth of mammalian tumors such as P-388 leukemia, L-1210 leukemia and B16 melanoma.

    摘要翻译: 本文命名为BMY-28121的新抗肿瘤抗生素是通过发酵链霉菌株K7331-113(ATCC 39897)产生的。 可以从其天然游离羟基形式(BMY-28121A)或甲基醚形式(BMY-28121B)的发酵液中回收的BMY-28121抑制革兰氏阳性菌和厌氧菌,并抑制哺乳动物肿瘤的生长,例如 P-388白血病,L-1210白血病和B16黑素瘤。

    BMY-28121, a new antitumor antibiotic
    9.
    发明授权
    BMY-28121, a new antitumor antibiotic 失效
    BMY-28121,一种新的抗肿瘤抗生素

    公开(公告)号:US4683230A

    公开(公告)日:1987-07-28

    申请号:US704973

    申请日:1985-02-25

    摘要: A new antitumor antibiotic designated herein as BMY-28121 is produced by fermentation of Streptomyces albus strain K731-113 (ATCC 39897). BMY-28121, which may be recovered from the fermentation broth in either its natural free hydroxy form (BMY-28121A) or methyl ether form (BMY-28121B), inhibits gram-positive bacteria and anaerobes and inhibits the growth of mammalian tumors such as P-388 leukemia, L-1210 leukemia and B16 melanoma.

    摘要翻译: 本文命名为BMY-28121的新型抗肿瘤抗生素通过Streptomyces albus菌株K731-113(ATCC 39897)的发酵产生。 可以从其天然游离羟基形式(BMY-28121A)或甲基醚形式(BMY-28121B)的发酵液中回收的BMY-28121抑制革兰氏阳性菌和厌氧菌,并抑制哺乳动物肿瘤的生长,例如 P-388白血病,L-1210白血病和B16黑素瘤。